Bleeding risk before percutaneous tracheostomy — FFICM MCQ

Correct answer: D — Defer and reassess after correcting modifiable bleeding and anatomical risks

The correct answer is D, defer and reassess after correcting modifiable bleeding and anatomical risks. This patient has three independent, correctable hazards before percutaneous tracheostomy: severe thrombocytopenia (42 x10^9/L), ongoing therapeutic unfractionated heparin, and an anterior jugular venous plexus overlying the planned puncture site, all of which markedly raise the risk of major bleeding and vascular injury during blind needle passage. Current practice supports optimising platelets and holding therapeutic anticoagulation before the procedure, and using pre-procedural ultrasound to reroute or reposition the tract away from aberrant vessels. There is no fixed calendar day that mandates proceeding regardless of risk; timing is individualised against physiological stability and correctable coagulopathy or anatomical hazards. Deferring allows platelet correction, heparin interruption with appropriate bridging, and ultrasound-guided site selection, converting a high-risk blind procedure into a safer, image-guided one. Why the other options are wrong: B. Proceed immediately because day 7 is mandatory: no UK or international guideline fixes a mandatory day for tracheostomy; timing is patient-specific and correctable risk factors should be addressed first. A. Perform blind landmark tracheostomy at the bedside: abandoning ultrasound in the presence of a demonstrated anterior venous plexus and severe thrombocytopenia on therapeutic heparin significantly increases the risk of catastrophic haemorrhage and vascular puncture. C. Stop heparin after the procedure: anticoagulation must be held before, not after, the procedure to reduce peri-procedural bleeding risk; stopping afterwards does nothing to mitigate the bleeding that occurs during tracheal puncture and dilatation. E. Extubate to avoid tracheostomy: this patient has ARDS with PEEP 14 cmH2O and is not described as ready for extubation; abandoning airway planning rather than correcting risk factors is not a reasoned clinical response to a reversible problem. Key point: Correct reversible bleeding risk (thrombocytopenia, therapeutic anticoagulation) and use ultrasound to map aberrant vasculature before proceeding, since tracheostomy timing should be individualised rather than fixed to a calendar day.

Reference: PMC (state of the art review): percutaneous tracheostomy platelet and anticoagulation optimisation and ultrasound use, https://pmc.ncbi.nlm.nih.gov/articles/PMC8411160/